Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPI | P34949 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | FKBP5 | Q13451 | 2/20 | 0.40 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.40 |
| ▸ | PDE4A | P27815 | 3/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.40 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL787280 | 0.93 | MPI (0.60) | MPICYP1A2CYP2C9FKBP5LTB4R | |
| SCHEMBL804299 | 0.85 | MPI (0.67) | MPICYP1A2CYP2C9FKBP5PDE4B | |
| SCHEMBL2379388 | 0.85 | MPI (0.53) | MPICYP1A2CYP2C9PDE4BPDE4A | |
| SCHEMBL805880 | 0.81 | MPI (0.60) | MPICYP1A2CYP2C9PDE4BPDE4A | |
| SCHEMBL787130 | 0.75 | MPI (1.00) | MPICYP1A2CYP2C9 | |
| SCHEMBL5767014 | 0.71 | MAPT (0.64) | CYP1A2CYP2C9KMT2A | |
| SCHEMBL787896 | 0.71 | CYP2C9 (0.79) | MPICYP1A2CYP2C9 | |
| SCHEMBL2149738 | 0.70 | MAPT (0.66) | CYP1A2CYP2C9KMT2A | |
| SCHEMBL17149979 | 0.69 | KMT2A (0.63) | CYP1A2CYP2C9KMT2A | |
| SCHEMBL5216700 | 0.69 | MGLL (0.62) | CYP1A2CYP2C9KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748632-B2 | Positive allosteric modulators of group II mGluRs | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120071503-A1 | POSITIVE ALLOSTERIC MODULATORS OF GROUP II MGLURS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2012-03-22 | — | — | US | disclosed |
| WO-2011116356-A2 | POSITIVE ALLOSTERIC MODULATORS OF GROUP II MGLURS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071503-A1 | POSITIVE ALLOSTERIC MODULATORS OF GROUP II MGLURS | GRM2, GRM1, GRIN2C | MPI 4265/4885CYP1A2 3286/4885CYP2C9 3909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.